Advancing therapy in people with suboptimally controlled basal insulin-treated type 2 diabetes: Subanalysis of the SoliMix trial in participants in Latin American countries.
Gustavo D FrechtelLeobardo Sauque-ReynaRicardo Choza-RomeroLuis AnguianoLydie Melas-MeltMaría Elena Sañudo-MauryPublished in: Diabetes, obesity & metabolism (2023)
Once-daily iGlarLixi provided better glycaemic control with weight benefit and less hypoglycaemia than twice-daily premix BIAsp 30. iGlarLixi may be a favourable alternative to premix BIAsp 30 in people with suboptimally controlled T2D to advance BI therapy in the LATAM region.